SiliconBeat

Santa Clara drug maker Xenoport said in a filing today it plans to sell 2.5 million more shares at $19 each in a secondary stock offering co-managed by top-shelf underwriters Morgan Stanley and Goldman Sachs.

The sale price was 11.6 percent lower than where Xenoport shares closed the day before the stock offering was announced. The company will sell the shares to the underwriters for  $17.91.

Xenoport appears to be taking advantage of good news it released last week when it reported Read the rest of this entry »

Have good news, will sell stock. That might be the logic behind a secondary offering of new shares by InterMune, the Brisbane biotechnology company whose stock price soared 28 percent to earlier this month after it said it would apply for approval in the Read the rest of this entry »